Gene therapy trial hopes to improve communication in angelman syndrome
Disease control
Recruiting now
This study tests a new gene therapy called MVX-220 for people with Angelman syndrome, a genetic condition that affects the nervous system. The therapy is given as a single injection into the fluid around the brain and spinal cord. The trial will include 12 children (ages 4-8) and…
Phase: PHASE1, PHASE2 • Sponsor: MavriX Bio, LLC • Aim: Disease control
Last updated May 17, 2026 08:01 UTC